Petiq Inc (NASDAQ:PETQ) has earned an average rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $27.00.

Several analysts have recently commented on PETQ shares. CIBC started coverage on Petiq in a report on Tuesday, August 15th. They set an “outperform” rating and a $28.00 target price on the stock. Raymond James Financial, Inc. started coverage on Petiq in a report on Tuesday, August 15th. They set an “outperform” rating and a $26.00 target price on the stock. Jefferies Group LLC started coverage on Petiq in a report on Tuesday, August 15th. They set a “hold” rating and a $25.00 target price on the stock. William Blair started coverage on Petiq in a report on Tuesday, August 15th. They set an “outperform” rating on the stock. Finally, Oppenheimer Holdings, Inc. started coverage on Petiq in a report on Tuesday, August 15th. They set an “outperform” rating and a $28.00 target price on the stock.

ILLEGAL ACTIVITY WARNING: “Petiq Inc (PETQ) Receives Consensus Recommendation of “Buy” from Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/09/petiq-inc-petq-receives-consensus-recommendation-of-buy-from-analysts.html.

Petiq (NASDAQ:PETQ) traded down 0.43% during midday trading on Friday, reaching $25.30. 109,234 shares of the company traded hands. The company has a 50-day moving average price of $23.82 and a 200-day moving average price of $26.54. Petiq has a 12-month low of $19.76 and a 12-month high of $26.99. The company’s market cap is $334.54 million.

About Petiq

PetIQ, Inc is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield.

Analyst Recommendations for Petiq (NASDAQ:PETQ)

Receive News & Ratings for Petiq Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petiq Inc and related companies with MarketBeat.com's FREE daily email newsletter.